ResearcherYonsei UniversityActive in the last 2 years
Seung Soo Hong
Matched on ORCID iD 0000-0001-9913-8437; OpenAlex author ID A5053733191. Sources: OpenAlex.
Their work
- Papers
- 13 (first author 5, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 25
2020: 1 paper · 2021: none · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 4 papers · 2026: 4 papers
Papers 13
- Feasibility and safety of minimally invasive distal pancreatosplenectomy in resectable and borderline resectable pancreatic cancer following neoadjuvant chemot… Co-author DOI 10.1007/s00464-025-12533-3↗
- Long-term oncologic outcomes and prognostic factors in resected stage IA pancreatic cancer: a retrospective cohort study. Co-author DOI 10.1007/s00464-026-12646-3↗
- Prospective Evaluation of Irreversible Electroporation With Clustered Electrodes as a Novel Palliative Approach for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3348/kjr.2025.1394↗
- Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cancer after curative surgery-toward future u… Co-author DOI 10.4174/astr.2026.110.2.76↗
- Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cance… First author DOI 10.1177/15347354251353499↗
- Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Curative Surgery. First author DOI 10.1245/s10434-025-18029-7↗
- Is There a Potential Oncologic Role for Local Therapy on Hepatic Metastasis in Patients Who Undergo Curative Pancreatectomy for Pancreatic Cancer? First author DOI 10.3349/ymj.2024.0078↗
- Immediate Postoperative AbnobaVISCUM® F as an Adjuvant Treatment in Patients Receiving Standard Care after Pancreatic Cancer Resection. Co-author DOI 10.3349/ymj.2024.0493↗
- Glucose-to-Lymphocyte Ratio (GLR) as an Independent Prognostic Factor in Patients with Resected Pancreatic Ductal Adenocarcinoma-Cohort Study. Co-author DOI 10.3390/cancers16101844↗
- Anticancer effect of locally applicable aptamer-conjugated gemcitabine-loaded atelocollagen patch in pancreatic cancer patient-derived xenograft models. Co-author DOI 10.1111/cas.15318↗
- Neoadjuvant FOLFIRINOX Followed by Pancreatoduodenectomy for Pancreatic Cancer in Patients with Previous Transhiatal Esophagectomy for Esophageal Cancer. First author DOI 10.1159/000525294↗
- Laparoscopic distal pancreatosplenectomy for left-sided pancreatic cancer in patients with radical subtotal gastrectomy for gastric cancer. First author DOI 10.14701/ahbps.22-016↗
- Feasibility and Safety of Laparoscopic Radical Distal Pancreatosplenectomy with Adrenalectomy in Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08670-9↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ho Kyoung Hwang · 12 shared papers, 2020–2026 · strength 3.39
- Paper Feasibility and safety of minimally invasive distal pancreatosplenectomy in resectable and borderline resectable pancre… DOI 10.1007/s00464-025-12533-3↗
- Paper Long-term oncologic outcomes and prognostic factors in resected stage IA pancreatic cancer: a retrospective cohort stud… DOI 10.1007/s00464-026-12646-3↗
- Paper Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Ch… DOI 10.1177/15347354251353499↗
- Chang Moo Kang · 11 shared papers, 2020–2026 · strength 2.80
- Paper Long-term oncologic outcomes and prognostic factors in resected stage IA pancreatic cancer: a retrospective cohort stud… DOI 10.1007/s00464-026-12646-3↗
- Paper Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Ch… DOI 10.1177/15347354251353499↗
- Paper Is There a Potential Oncologic Role for Local Therapy on Hepatic Metastasis in Patients Who Undergo Curative Pancreatec… DOI 10.3349/ymj.2024.0078↗
- Sung Hyun Kim · 8 shared papers, 2022–2026 · strength 2.54
- Paper Feasibility and safety of minimally invasive distal pancreatosplenectomy in resectable and borderline resectable pancre… DOI 10.1007/s00464-025-12533-3↗
- Paper Long-term oncologic outcomes and prognostic factors in resected stage IA pancreatic cancer: a retrospective cohort stud… DOI 10.1007/s00464-026-12646-3↗
- Paper Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Ch… DOI 10.1177/15347354251353499↗
- So Jeong Yoon · 2 shared papers, 2025–2026 · strength 0.53
- Paper Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cance… DOI 10.4174/astr.2026.110.2.76↗
- Paper Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Cu… DOI 10.1245/s10434-025-18029-7↗
- Jin Seok Heo · 2 shared papers, 2025–2026 · strength 0.53
- Paper Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cance… DOI 10.4174/astr.2026.110.2.76↗
- Paper Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Cu… DOI 10.1245/s10434-025-18029-7↗
- In Woong Han · 2 shared papers, 2025–2026 · strength 0.53
- Paper Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cance… DOI 10.4174/astr.2026.110.2.76↗
- Paper Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Cu… DOI 10.1245/s10434-025-18029-7↗
- Hongbeom Kim · 2 shared papers, 2025–2026 · strength 0.53
- Paper Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cance… DOI 10.4174/astr.2026.110.2.76↗
- Paper Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Cu… DOI 10.1245/s10434-025-18029-7↗
- Sang Hyun Shin · 2 shared papers, 2025–2026 · strength 0.53
- Paper Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cance… DOI 10.4174/astr.2026.110.2.76↗
- Paper Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Cu… DOI 10.1245/s10434-025-18029-7↗
- Woo Jung Lee · 3 shared papers, 2020–2022 · strength 0.51
- Paper Laparoscopic distal pancreatosplenectomy for left-sided pancreatic cancer in patients with radical subtotal gastrectomy… DOI 10.14701/ahbps.22-016↗
- Paper Neoadjuvant FOLFIRINOX Followed by Pancreatoduodenectomy for Pancreatic Cancer in Patients with Previous Transhiatal Es… DOI 10.1159/000525294↗
- Paper Feasibility and Safety of Laparoscopic Radical Distal Pancreatosplenectomy with Adrenalectomy in Advanced Pancreatic Ca… DOI 10.1245/s10434-020-08670-9↗
- Juwan Kim · 2 shared papers, 2022–2025 · strength 0.49
- Paper Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Ch… DOI 10.1177/15347354251353499↗
- Paper Neoadjuvant FOLFIRINOX Followed by Pancreatoduodenectomy for Pancreatic Cancer in Patients with Previous Transhiatal Es… DOI 10.1159/000525294↗
- In Soo Cho · 1 shared paper, 2026 · strength 0.39
- Jun Hyung Kim · 1 shared paper, 2025 · strength 0.33
- Seoung Yoon Rho · 1 shared paper, 2025 · strength 0.30
- Munseok Choi · 1 shared paper, 2025 · strength 0.30
- Su Hyeong Park · 1 shared paper, 2024 · strength 0.26
- Man Deuk Kim · 1 shared paper, 2026 · strength 0.24
- Moon Jae Chung · 1 shared paper, 2026 · strength 0.24
- Joon Ho Kwon · 1 shared paper, 2026 · strength 0.24
- Tae Yang Choi · 1 shared paper, 2026 · strength 0.24
- Seungmin Bang · 1 shared paper, 2026 · strength 0.24
- Seung‐seob Kim · 1 shared paper, 2022 · strength 0.19
- Kang Hee Lee · 1 shared paper, 2022 · strength 0.19
- Choong‐kun Lee · 1 shared paper, 2022 · strength 0.16
- Sung Hwan Lee · 1 shared paper, 2022 · strength 0.16
- Jung Hwan Lee · 1 shared paper, 2022 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.